Jacobs Levy Equity Management’s Janux Therapeutics JANX Stock Holding History

Jacobs Levy Equity Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$219K	Buy	+14,238	New	+$206K	﹤0.01%	906

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Jacobs Levy Equity Management's JANX Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Janux Therapeutics (JANX) in Q2 2026: 14,238 shares worth $219K. The stake represents ﹤0.01% of the portfolio and ranks #906 among its holdings.

198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Jacobs Levy Equity Management held 14,238 shares of Janux Therapeutics worth $219K as of Q2 2026.
Janux Therapeutics was a new Jacobs Levy Equity Management position in Q2 2026.
Janux Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #906 holding.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.